Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary structure-based drug design platform has enabled us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, migraine, addiction, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple partners including AstraZeneca, Cubist, Morphosys and Takeda.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Oct 2, 2015
Heptares wins Best UK Biotech Dealmaker Award at OBN Annual Awards 2015
Sep 28, 2015

Heptares Awarded $5.5 Million Research & Development Grant from the US National Institute on Drug Abuse (NIDA)


Oct 22-24, 2015
Great Lakes GPCR Retreat
Hockley Valley, Canada
Presenting: James Errey

Oct 29-30, 2015
Drug Discovery USA Congress
Boston, MA, USA
Presenting: Ali Jazayeri

© 2012-2015 Heptares Therapeutics